Abstract 1594P
Background
The COVID-19 pandemic impacted cancer diagnosis and treatment. However, little is known about end-of-life (EOL) cancer care during the pandemic. Therefore, the aim of this study was to investigate potentially inappropriate EOL hospital care in patients dying with cancer before and during the COVID-19 pandemic.
Methods
This population-based study used linked data from the Netherlands Cancer Registry and the Dutch National Hospital Care Registration. Patients deceased between January 2018 and May 2021, who were diagnosed with cancer or received hospital care for cancer in the year preceding death were included. Potentially inappropriate EOL care was compared between four periods during the COVID-19 pandemic and corresponding periods in 2018/2019. Six international indicators of potentially inappropriate care in the last month of life were used: chemotherapy administration, >1 emergency room contact, >1 hospitalization, hospitalization >14 days, intensive care unit admission and hospital death.
Results
In total, 112,919 patients were included. Less patients received potentially inappropriate EOL hospital care during the COVID-19 pandemic compared to the preceding years, most pronounced during the first COVID-19 peak (22,4% vs 26,0%). Regression analysis showed lower odds of potentially inappropriate EOL care during all COVID-19 periods (ranging between OR 0.81; 95%CI:0.74-0.88 and OR 0.92; 95%CI 0.87-0.97) after adjusting for age, gender and cancer type. For the separate indicators, less patients experienced multiple or long hospitalizations, intensive care unit admission or a hospital death during the pandemic.
Conclusions
Cancer patients experienced less potentially inappropriate EOL hospital care during the COVID-19 pandemic. Because lack of capacity, patients avoiding hospital and increased awareness for triaging and advance care planning (ACP) may all have contributed, it is unclear whether this reflects better quality care. Nevertheless, retaining awareness for triaging and ACP is important because it may help provide appropriate EOL care to an increasing number of patients in the context of limited resources.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
COVID and Cancer NL Consortium.
Funding
The Netherlands Organisation for Health Research and Development (ZonMW).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1867P - A cross-sectional examination of information disclosure and health literacy amongst patients with lymphoma
Presenter: Steve Kalloger
Session: Poster session 05
1868P - Challenges for shared decision making in incurable cancer, with a focus on health literacy
Presenter: Chloe Holden
Session: Poster session 05
1871P - The PainRELife ecosystem: A new aid for improving clinical care and shared decision-making in breast cancer patients with chronic pain
Presenter: Marianna Masiero
Session: Poster session 05
1872P - Financial distress of a cancer disease in Germany: A new patient reported outcome measure (PROM) and first results from a bi-centered cross-sectional analysis
Presenter: Sophie Pauge
Session: Poster session 05
1873P - Patients with myeloproliferative neoplasms and self-care behaviours: Preliminary data of a cross-sectional study
Presenter: Valentina Biagioli
Session: Poster session 05
1874P - Beliefs about chemotherapy in Tunisian patients newly diagnosed with cancer
Presenter: Hadhemi Ayadi
Session: Poster session 05
1875P - Behind the use of ChatGPT for oncological purposes: Fears and challenges
Presenter: Ilaria Durosini
Session: Poster session 05
1876P - Cancer stigma: How Tunisian patients perceive their cancer
Presenter: sofiene Fendri
Session: Poster session 05
1877P - Meaning-making in the re-entry phase: A qualitative focus group study with patients with breast cancer and melanoma
Presenter: Anna Visser
Session: Poster session 05